Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles.
Hautakangas H, Winsvold BS, Ruotsalainen SE, Bjornsdottir G, Harder AVE, Kogelman LJA, Thomas LF, Noordam R, Benner C, Gormley P, Artto V, Banasik K, Bjornsdottir A, Boomsma DI, Brumpton BM, Burgdorf KS, Buring JE, Chalmer MA, de Boer I, Dichgans M, Erikstrup C, Färkkilä M, Garbrielsen ME, Ghanbari M, Hagen K, Häppölä P, Hottenga JJ, Hrafnsdottir MG, Hveem K, Johnsen MB, Kähönen M, Kristoffersen ES, Kurth T, Lehtimäki T, Lighart L, Magnusson SH, Malik R, Pedersen OB, Pelzer N, Penninx BWJH, Ran C, Ridker PM, Rosendaal FR, Sigurdardottir GR, Skogholt AH, Sveinsson OA, Thorgeirsson TE, Ullum H, Vijfhuizen LS, Widén E, van Dijk KW, International Headache Genetics Consortium, HUNT All-in Headache, Danish Blood Donor Study Genomic Cohort, Aromaa A, Belin AC, Freilinger T, Ikram MA, Järvelin MR, Raitakari OT, Terwindt GM, Kallela M, Wessman M, Olesen J, Chasman DI, Nyholt DR, Stefánsson H, Stefansson K, van den Maagdenberg AMJM, Hansen TF, Ripatti S, Zwart JA, Palotie A, Pirinen M. · 2022
Read Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. by Hautakangas H, Winsvold BS, Ruotsalainen SE, Bjornsdottir G, Harder AVE, Kogelman LJA, Thomas LF, Noordam R, Benner C, Gormley P, Artto V, Banasik K, Bjornsdottir A, Boomsma DI, Brumpton BM, Burgdorf KS, Buring JE, Chalmer MA, de Boer I, Dichgans M, Erikstrup C, Färkkilä M, Garbrielsen ME, Ghanbari M, Hagen K, Häppölä P, Hottenga JJ, Hrafnsdottir MG, Hveem K, Johnsen MB, Kähönen M, Kristoffersen ES, Kurth T, Lehtimäki T, Lighart L, Magnusson SH, Malik R, Pedersen OB, Pelzer N, Penninx BWJH, Ran C, Ridker PM, Rosendaal FR, Sigurdardottir GR, Skogholt AH, Sveinsson OA, Thorgeirsson TE, Ullum H, Vijfhuizen LS, Widén E, van Dijk KW, International Headache Genetics Consortium, HUNT All-in Headache, Danish Blood Donor Study Genomic Cohort, Aromaa A, Belin AC, Freilinger T, Ikram MA, Järvelin MR, Raitakari OT, Terwindt GM, Kallela M, Wessman M, Olesen J, Chasman DI, Nyholt DR, Stefánsson H, Stefansson K, van den Maagdenberg AMJM, Hansen TF, Ripatti S, Zwart JA, Palotie A, Pirinen M. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8837554.txt.
Introduction
Hautakangas and co-authors report the largest genetic study of migraine to date. Migraine affects over a billion people worldwide. Its genetic roots, though, stayed largely unknown. The team ran a genome-wide association study. It covered 102,084 migraine cases and 771,257 controls. The scan found 123 risk loci. Of those, 86 were previously unknown.
The authors then split results by migraine subtype. Some variants raised risk only with aura. Others raised risk only without aura. Nine variants raised risk for both forms. New loci include genes for recent migraine drug targets. Those targets involve a pain peptide and a serotonin receptor. Signals clustered in both blood vessel and brain tissue. The study supports a neurovascular view of migraine.
Catalog record
| CREATOR | Hautakangas H, Winsvold BS, Ruotsalainen SE, Bjornsdottir G, Harder AVE, Kogelman LJA, Thomas LF, Noordam R, Benner C, Gormley P, Artto V, Banasik K, Bjornsdottir A, Boomsma DI, Brumpton BM, Burgdorf KS, Buring JE, Chalmer MA, de Boer I, Dichgans M, Erikstrup C, Färkkilä M, Garbrielsen ME, Ghanbari M, Hagen K, Häppölä P, Hottenga JJ, Hrafnsdottir MG, Hveem K, Johnsen MB, Kähönen M, Kristoffersen ES, Kurth T, Lehtimäki T, Lighart L, Magnusson SH, Malik R, Pedersen OB, Pelzer N, Penninx BWJH, Ran C, Ridker PM, Rosendaal FR, Sigurdardottir GR, Skogholt AH, Sveinsson OA, Thorgeirsson TE, Ullum H, Vijfhuizen LS, Widén E, van Dijk KW, International Headache Genetics Consortium, HUNT All-in Headache, Danish Blood Donor Study Genomic Cohort, Aromaa A, Belin AC, Freilinger T, Ikram MA, Järvelin MR, Raitakari OT, Terwindt GM, Kallela M, Wessman M, Olesen J, Chasman DI, Nyholt DR, Stefánsson H, Stefansson K, van den Maagdenberg AMJM, Hansen TF, Ripatti S, Zwart JA, Palotie A, Pirinen M. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 82 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles By Heidi Hautakangas, Bendik S Winsvold, Sanni E Ruotsalainen, Gyda Bjornsdottir, Aster V E Harder, Lisette J A Kogelman, Laurent F Thomas, Raymond Noordam, Christian Benner, Padhraig Gormley, Ville Artto, Karina Banasik Published in: Nature Genetics DOI: 10.1038/s41588-021-00990-0 ABSTRACT Abstract Migraine affects over a billion individuals worldwide but its genetic underpinning remains largely unknown. Here, we performed a genome-wide association study of 102,084 migraine cases and 771,257 controls and identified 123 loci, of which 86 are previously unknown. These loci provide an opportunity to evaluate shared and distinct genetic components in the two main migraine subtypes: migraine with aura and migraine without aura. Stratification of the risk loci using 29,679 cases with subtype information indicated three risk variants that seem specific for migraine with aura (in HMOX2, CACNA1A and MPPED2), two that seem specific for migraine without aura (near SPINK2 and near FECH) and nine that increase susceptibility for migraine regardless of subtype. The new risk loci include genes encoding recent migraine-specific drug targets, namely calcitonin gene-related peptide (CALCA/CALCB) and serotonin 1F receptor (HTR1F). Overall, genomic annotations among migraine-associated variants were enriched in both vascular and central nervous system tissue/cell types, supporting unequivocally that neurovascular mechanisms underlie migraine pathophysiology. Subject terms: Migraine, Genome-wide association studies MAIN Migraine is a highly prevalent brain disorder characterized by disabling attacks of moderate-to-severe pulsating and usually one-sided headache that may be aggravated by physical activity, and can be associated with symptoms such as a hypersensitivity to light and sound, nausea and vomiting1. Migraine has a lifetime prevalence of 15–20% and is ranked as the second most disabling condition in terms of years lived with disability2,3. Migraine is three times more prevalent in females than in males. For about one-third of patients, migraine attacks often include an aura phase4 characterized by transient neurological symptoms such as scintillations. Hence, the two main migraine subtypes are defined as migraine with aura (MA) and migraine without aura (MO). It has been debated for decades whether or not the migraine subtypes are in fact two separate disorders5–7, and, if so, what the underlying causes are. Prevailing theories about migraine pathophysiology emphasize neuronal and/or vascular dysfunction8,9. Current knowledge of disease mechanisms comes largely from studies of a rare monogenic subform of MA—familial hemiplegic migraine—for which three ion transporter genes (CACNA1A, ATP1A2 and SCN1A) have been identified10. The common forms of migraine (MA and MO) instead have a complex polygenic architecture with an increased familial relative risk5, increased concordance in monozygotic twins11 and a heritability of 40–60%12. The largest genome-wide association study (GWAS) thus far, with 59,674 cases and 316,078 controls, reported 38 genomic loci that confer migraine risk13. Subsequent analyses of these GWAS data showed enrichment of migraine signals near activating histone marks specific to cardiovascular and central nervous system (CNS) tissues14, as well as for genes expressed in vascular and smooth muscle tissues13. Other smaller GWAS15–21 have suggested ten additional loci. Of note, the previous datasets were too small to perform a meaningful comparison of the genetic background between migraine subtypes. As migraine is globally the second largest contributor to years lived with disability2,3, there is clearly a large need for new treatments. Triptans, that is, serotonin 5-HT1B/1D receptor agonists, are migraine-specific acute treatments for the headache phase but are not effective in every patient, whereas preventive medication is far from satisfactory22. Recent promising alternatives for acute treatment are serotonin 5-HT1F receptor agonists (‘ditans’)23 and small-molecule calcitonin gene-related peptide (CGRP) receptor antagonists (‘gepants’)24,25. For preventive treatment, monoclonal antibodies (mAbs) targeting CGRP or its receptor have recently proven effective26, and new gepants for migraine prevention are under development27. Still, there remains an urgent need for treatment options for patients who do not respond to existing treatments. Genetics has proven promising in developing new therapeutic hypotheses in other prevalent complex diseases, such as cardiovascular disease28 and type 2 diabetes29, and we anticipate that large genetic studies of migraine could also yield similar insights. We conducted a GWAS meta-analysis of migraine by adding to the previous meta-analysis13 42,410 new migraine cases from four study collections (Table 1). This increased the number of migraine cases by 71% for a total sample of 102,084 cases and 771,257 controls. Furthermore, we assessed the subtype specificity of the risk loci in 8,292 new MA and 6,707 new MO cases in addition to the 6,332 MA and 8,348 MO cases used previously13 (Table 2). Here, we report 123 genomic loci, of which 86 are previously unknown, and include the first four loci that reach genome-wide significance (P < 5 × 10−8) in MA. Our subtype data show compellingly that migraine risk is conferred both by risk loci that seem specific for only one subtype as well as by loci that are shared by both subtypes. Our findings also include new risk loci containing target genes of recent migraine drugs acting on the CGRP pathway and the serotonin 5-HT1F receptor. Finally, our data support the concept that migraine is brought about by both neuronal and vascular genetic factors, strengthening the view that migraine is truly a neurovascular disorder. [Table: Five migraine study collections included in the meta-analysis] [Table: Study collections included in MO and MA subtype analyses] RESULTS Genome-wide meta-analysis We combined data on 873,341 individuals of European ancestry (102,084 cases and 771,257 controls) from five study collections (Table 1 and Supplementary Table 1) and analyzed 10,843,197 common variants (Methods). Despite different approaches to the ascertainment of migraine cases across studies, pairwise genetic correlations were all near 1 (Supplementary Table 2), as determined by linkage disequilibrium (LD) score (LDSC) regression30, showing high genetic and phenotypic similarity across the studies, justifying their meta-analysis. Pairwise LDSC intercepts were all near 0, indicating little or no sample overlap (Supplementary Table 2). The genomic inflation factor (λGC) of the fixed-effect meta-analysis results was 1.33 (Supplementary Fig. 1), which is in line with other large meta-analyses31–33 and is as expected for a polygenic trait34. The univariate LDSC35 intercept was 1.05 (s.e. 0.01), which, being close to 1.0, suggests that most of the genome-wide elevation of the association statistics comes from true additive polygenic effects rather than from a confounding bias such as population stratification. The LDSC analysis showed a linear trend between the variant’s LD score and its association with migraine, as expected from a highly polygenic phenotype such as migraine (Supplementary Fig. 2). The SNP heritability estimate from LDSC was 11.2% (95% confidence interval (CI) 10.8–11.6%) on a liability scale when assuming a population prevalence of 16%. We identified 8,117 genome-wide significant (GWS; P < 5 × 10−8) variants represented by 170 LD-independent index variants (r2 < 0.1). We defined the risk loci by including all variants in high LD (r2 > 0.6) with the index variants and merged loci that were closer than 250 kb (Methods). This resulted in 123 independent risk loci (Fig. 1, Supplementary Table 3a and Supplementary Data 1 and 2). Of the 123 loci, 86 are previously unknown, whereas 36 overlap with the previously reported 47 autosomal risk loci (Supplementary Table 4) and one with the previously reported X chromosome risk locus. Of the 11 previously reported migraine risk loci that were not